ARS PHARMACEUTICALS

FDA approves neffy (epinephrine nasal spray) 2 mg for Type I Allergic Reactions, including anaphylaxis, in adults and children ≥30 kg, marking the first needle-free epinephrine treatment innovation in over 35 years.

neffy, the first needle-free epinephrine nasal spray for severe allergic reactions, including anaphylaxis, approved by FDA for adults and children ≥30 kg. Offers a new, easy-to-use alternative to injections, aiming to improve treatment accessibility and reduce anxiety. Expected to be available in the U.S. within eight weeks post-approval.

FDA approved Neffy, a needle-free nasal spray for emergency allergic reactions, offering an alternative to EpiPen. Suitable for adults and children over 66 pounds, it simplifies epinephrine administration, potentially increasing usage among those with needle fears. Approved after studies showed effective epinephrine absorption, despite initial regulatory hesitation.

The FDA approved Neffy, the first nasal spray epinephrine for anaphylaxis, offering a needle-free alternative for those over 66 pounds. Comparable to injectable epinephrine, Neffy aims to reduce treatment barriers, especially for children. Priced at $710 for a two-pack, with lower co-pays and a 30-month shelf life, it's expected to be available in the US within eight weeks. ARS Pharmaceuticals anticipates significant uptake, similar to Narcan, and plans to seek approval for younger children.

neffy®, a needle-free epinephrine nasal spray for anaphylaxis, is now available by prescription. Approved by the FDA, it offers an alternative to auto-injectors, with similar efficacy and mild side effects. Studies show high patient preference for nasal sprays over injections. neffy is compact, easy to use, and accessible through various pricing programs.